Tag: Stellarex
LINC 2021: Long-term data show sustained efficacy and safety of paclitaxel...
A key theme among the late-breaking trial data presented at LINC 2021 (The Leipzig Interventional Course; 25–29 January, online) was the emergence of long-term...
LINC 2021: Five-year ILLUMENATE results confirm safety profile of Philips Stellarex...
Royal Philips has announced the final, five-year results of two randomised controlled trials (RCTs) that show no difference in all-cause mortality between patients treated...
ILLUMENATE four-year pooled analysis has “brought increased clarity” to the paclitaxel...
Sean Lyden (Cleveland, USA), current VIVA Board president, speaks to Vascular News about his two years at the helm, which began with the “controversy on...
Four-year results from patient-level meta-analysis confirm safety profile of Philips Stellarex...
Royal Philips today announced the results of a patient-level meta-analysis that confirms the safety profile of its Stellarex drug-coated balloon (DCB) at four years....
New data reconfirm long-term safety profile of the Philips Stellarex low-dose...
Royal Philips recently announced the four-year results from the ILLUMENATE European randomised controlled trial (EU RCT). The Stellarex drug-coated balloon (DCB) cohort demonstrated similar...
LINC 2020: Four-year ILLUMENATE data reaffirm safety profile of Stellarex
Philips today announced four-year results from the randomised controlled ILLUMENATE pivotal trial in the USA. The data show similar mortality rates through four years...
Philips receives FDA approval for low-dose drug-coated balloons
Philips has received US Food and Drug Administration (FDA) approval for two Stellarex 0.035” low-dose (200mm and 150mm) drug-coated balloons for the treatment of...
Late-breaking ILLUMENATE data demonstrate three-year safety and efficacy for Stellarex DCB
Three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European randomised controlled trial (EU RCT) have been presented in a late-breaking trial session...
New data release at LINC 2019 reinforces safety profile of low-dose...
Sean Lyden (Cleveland, USA) and Fabrizio Fanelli (Rome, Italy) discuss the safety and future of drug-coated balloons (DCB) in light of the latest pooled...
Latest data from Philips reinforces the safety profile of Stellarex low-dose...
A new pooled analysis of patient-level data from Philips demonstrates the “strong safety profile” of the company's Stellarex drug-coated balloon (DCB) in above-the-knee studies,...
First US patient enrolled in ILLUMENATE BTK study of Stellarex 0.014...
The first US patient has been enrolled in the Stellarex ILLUMENATE below-the-knee (BTK) investigational device exemption (IDE) study, led by principal investigators Bill Gray...
Similar patency outcomes in women and men treated with Stellarex DCB
A study presented at VIVA 2018 (5–8 November, Las Vegas, USA) by Maureen Kohi, associate professor of Clinical Radiology, University of California, San Francisco,...
Two-year ILLUMENATE Global data find 72.4% primary patency with Stellarex DCB
After two years of follow-up, the ILLUMENATE Global study has confirmed the durability of the Stellarex drug-coated balloon (Spectranetics/Philips) with primary patency rates comparable...
Two-year efficacy of Philips’ Stellarex 0.035” low-dose drug-coated balloon demonstrated
Philips has announced the two-year results from the ILLUMENATE European randomised clinical trial (EU RCT) demonstrating the efficacy of the Philips Spectranetics’ Stellarex 0.035”...
Spectranetics announces FDA approval of Stellarex drug-coated balloon
Spectranetics has announced receipt of US Food and Drug Administration (FDA) pre-market approval of the Stellarex drug-coated balloon (DCB), designed to restore and maintain blood flow...
Global cohorts report drug-coated balloon success above the knee and “promising”...
Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...
Combined 12-month analysis of ILLUMENATE EU and US trials presented at...
At LINC 2017 (24–27 January, Leipzig, Germany), Sean Lyden (Cleveland Clinic, Cleveland, USA) presented an update on the 12-month results of the European and...
Positive results for Spectranetics Stellarex demonstrated in ILLUMENATE 12-month data
The final 12-month results of the Stellarex (Spectranetics) drug-coated balloon ILLUMENATE Global Study have found high primary patency and freedom from clinically driven target...
Spectranetics receives CE mark for Stellarex 0.014 drug-coated balloon
Spectranetics’ Stellarex 0.014” drug-coated angioplasty balloon has received the CE mark.
The Stellarex 0.014” device is designed to treat small vessels, below-the-knee disease, and challenging...
Stellarex ILLUMENATE 12-month pivotal results are “top-tier” in complex patients
Spectranetics has announced that the final 12-month results of the Stellarex drug-coated balloon ILLUMENATE pivotal trial have been presented at the Transcatheter Cardiovascular Therapeutics...
Spectranetics files FDA pre-market approval application for the Stellarex drug-coated balloon
Spectranetics has submitted its pre-market approval application for the Stellarex drug-coated angioplasty balloon to the US Food and Drug Administration (FDA). Stellarex is designed to restore...
First randomised Stellarex DCB data show 12-month outcomes superior to percutaneous...
Marianne Brodmann of Medical University Graz, Austria, has presented the final 12-month results of the Stellarex (Spectranetics) ILLUMENATE drug-coated balloon European randomised clinical trial...
